[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636443":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":48,"responsibleParty":98,"collaborators":101,"id":105,"slug":106,"hasResults":107,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":107,"sex":113,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":42,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":130,"whyStopped":42,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"The University of Texas Health Science Center at San Antonio","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nebulized Tranexamic Acid","EXPERIMENTAL","Subjects will be adminstered nebulized TXA post-tonsillectomy if they return to the emergency room with hemorrhage after surgery",[13],"Drug: Tranexamic Acid Injectable Product",{"label":15,"type":16,"description":17,"interventionNames":18},"Nebulized Saline","PLACEBO_COMPARATOR","Subjects will be adminstered nebulized saline post-tonsillectomy if they return to the emergency room with hemorrhage after surgery",[19],"Other: Normal Saline",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tranexamic Acid Injectable Product","Participants will receive three doses of TXA 500 mg (5 mL of TXA 100mg\u002Fml) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter\u002Fminute of gas flow.",[9],[27],"TXA 100mg\u002Fml",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Normal Saline","Participants will receive three 5 ml doses of placebo (normal saline) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter\u002Fminute of gas flow.",[15],[33],"0.9% saline solution",[35],{"name":36,"affiliation":5,"role":37},"Andrew D Meyer, MD, MS","PRINCIPAL_INVESTIGATOR",[39,44],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","210-567-4424",null,"meyera@uthscsa.edu",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Stephanie Perez, MHA","(210) 450-8973","perezs11@uthscsa.edu",[49,66,81],{"facility":50,"status":42,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"University of California at Davis Medical Center","Davis","California","95819","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-121.74052,38.54491,{"lat":60,"lon":59},[63],{"name":64,"role":40,"phone":42,"phoneExt":42,"email":65},"Daniel Nishijima, MD","dnishijima@ucdavis.edu",{"facility":67,"status":42,"city":68,"state":69,"zip":70,"country":54,"countryCode":55,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Hasbro Childrens' Hospital","Providence","Rhode Island","02903",{"type":57,"coordinates":72},[73,74],-71.41283,41.82399,{"lat":74,"lon":73},[77],{"name":78,"role":40,"phone":79,"phoneExt":42,"email":80},"Thomas Chun, MD","401-444-6680","Thomas_Chun@brown.edu",{"facility":82,"status":42,"city":83,"state":84,"zip":85,"country":54,"countryCode":55,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"University Hospital","San Antonio","Texas","78229",{"type":57,"coordinates":87},[88,89],-98.49363,29.42412,{"lat":89,"lon":88},[92,95],{"name":36,"role":40,"phone":93,"phoneExt":42,"email":94},"210-562-5816","MEYERA@UTHSCSA.EDU",{"name":96,"role":40,"phone":97,"phoneExt":42,"email":47},"Stephanie Perez","210-450-8973",{"type":37,"investigatorFullName":99,"investigatorTitle":100,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Andrew D. Meyer","Associate Professor",[102],{"name":103,"class":104},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100636443","early-phase-1-teapot-study-multisite-100636443",false,"NCT07565753","TEAPOT Study Multisite","TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage (TEAPOT): A Multi-center Feasibility Study","TEAPOT","Inclusion Criteria:\n\n1. Received a tonsillectomy\n2. Presents to the ED with secondary\\* post-tonsillectomy hemorrhage\n3. Children between age of 2 to 17 years of age (i.e., before their 18th birthday) \\*Secondary post-tonsillectomy hemorrhage is defined as greater than 24 hours from their primary tonsillectomy operation (arrival in recovery\u002FPACU).\n\nExclusion Criteria:\n\n1. Known and documented bleeding or clotting disorder.\n2. Known pregnancy.\n3. Patients with known hypersensitivity or allergic response to tranexamic acid.\n4. Parents or guardians who cannot communicate in English or Spanish.\n5. Intubation prior to enrollment.\n6. Previously enrolled patients.","ALL","2 Years","17 Years",{"count":117,"type":118},30,"ESTIMATED","INTERVENTIONAL",[121],"EARLY_PHASE1","After a child has their tonsils removed, sometimes they might bleed which can be a problem. There is a special mist medicine called nebulized tranexamic acid (TXA) that might help stop the bleeding without having to touch the sore spot. If this mist works well, it could help kids get better by making sure they don't have to go back for more surgery or need blood from someone else. Not having another surgery is good because it means kids won't have to sleep under medicine again, which can sometimes be risky for their brains and breathing, and they won't feel as scared or hurt.",[124,125],"Hemorrhage, Surgical","Tonsillar Bleeding",[127,128,129],"Tranexamic Acid","Nebulizer","Post tonsillectomy hemorrhage","NOT_YET_RECRUITING","2026-05-21",{"date":133,"type":134},"2026-05-26","ACTUAL",{"date":136,"type":118},"2026-07",{"date":138,"type":118},"2028-09-30",{"name":5,"class":6},3]